Navigation Links
PharmAthene Announces Closing of $15 Million Public Offering
Date:11/3/2010

t historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there can be no assurance that PharmAthene will satisfy the NYSE Amex continuing listing standards by January 26, 2012, or that during the compliance period the Exchange will not deem PharmAthene's progress toward compliance inadequate.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene Appoints Eric I. Richman President and Chief Executive Officer
2. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
3. PharmAthene Completes Previously Announced Registered Direct Offering
4. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
5. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
8. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
9. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
10. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
11. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... Drug Discovery Technologies - A Global Market Overview ... The development of new drugs for treating ... in addition to consuming a lot of time. ... involves the utilizing high-throughput screening of large chemical ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Global Generic Pharmaceuticals ... The Global Generic Pharmaceuticals Industry Report ... evaluation of the Global Generic Pharmaceuticals Industry Report. ...
... Ill., Dec. 8, 2010 Life Spine announced today ... the OCTAVE Posterior Fusion System, which is intended for ... achieving fusion in conjunction with bone graft. The U.S. ... to the OCTAVE System last month. ...
Cached Medicine Technology:Reportlinker Adds Global Generic Pharmaceuticals Industry Report 2Reportlinker Adds Global Generic Pharmaceuticals Industry Report 3Reportlinker Adds Global Generic Pharmaceuticals Industry Report 4Reportlinker Adds Global Generic Pharmaceuticals Industry Report 5Reportlinker Adds Global Generic Pharmaceuticals Industry Report 6Reportlinker Adds Global Generic Pharmaceuticals Industry Report 7
(Date:9/2/2014)... Viejo, California (PRWEB) September 02, 2014 ... plugins have announced a new ProIntro Lesson from Pixel ... to create easy and fresh-looking titles,” said Christina Austin, ... professional and armature, ProIntro is a definite game changer.” ... with the ProIntro Lesson from Pixel Film Studios. ProIntro ...
(Date:9/2/2014)... 02, 2014 Aeroflow Healthcare, an industry ... Southeast, announced the opening of its new office to ... is: 310 Business Parkway, Suite D, Greer, SC 29651. ... patients with a more convenient location in the Greenville ... Healthcare and the physicians, hospitals and patients we serve, ...
(Date:9/2/2014)... September 02, 2014 NOVAtime Technology, ... solution development company, announced today that Avon Health ... has upgraded to NOVAtime 4000 Time and ... with NOVAtime’s latest smart clock, the NT7000 ... Valley of Connecticut is an award-winning nursing facility ...
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 Attorney ... as the 2015 "Lawyer of the Year" for Medical ... Lubin & Meyer PC, Boston, and has been selected for ... 2008. Only one lawyer in each practice area and designated ... based on particularly impressive voting averages received during the peer-review ...
(Date:9/2/2014)... September 02, 2014 “Harmonicas have ... a decade, primarily to help people with COPD ... are three developed systems,” says Dana Keller, PhD, ... differ, the goals are much the same – ... some type of harmonica.” , The three approaches ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3
... ... offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital voice recorder ... consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in the United States, ...
... 9 June 2009 - Researchers have been seeking ... impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) ... may contribute to the underlying neurobiology of this ... stimulate NMDA receptors administered large amounts of substances, ...
... DNA binding compound has proved surprisingly effective at binding to ... touched within two minutes. The DNA binding properties of the ... the University of Warwick by Professor Mike Hannon and Professor ... of Birmingham). However the strength of its antibiotic powers have ...
... June 9 BioMarin Pharmaceutical Inc. (Nasdaq: ... clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) ... expects to initiate the Phase 2 clinical study in ... (IRB) approval from the clinical trial sites. The ...
... Protein Widely Expressed on Tumors and Tumor Blood Vessel ... Morphotek(R), Inc., a subsidiary of Eisai Corporation of North ... (FDA) cleared its investigational new drug (IND) application to ... tumors. MORAb-004 targets endosialin, a protein expressed on cells ...
... Bruce Matter has joined healthcare IT software provider, ... growth and client satisfaction. Peminic, with offices in Princeton, ... solutions to over 400 acute care and other healthcare ... legal matters. , , Teaming with hospitals, health ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:Animal model for schizophrenia identifies a novel approach for treating cognitive impairments 2Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 3Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 4Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... anti-TG test kit is a solid phase ... It is designed for the quantitative measurement ... in serum or plasma. The microplate is ... controls and patient samples are pipetted into ...
Medicine Products: